The Dual-Agonist Idea
A glucagon/GLP-1 dual agonist is a single molecule designed to activate two different receptors at once: the GLP-1 receptor and the glucagon receptor. The thinking behind combining them is that each contributes something the other does not, so a well-balanced dual agonist might achieve more than a GLP-1 drug alone.
What Each Arm Does
GLP-1 activation is associated with appetite suppression and favorable effects on glucose handling. These are the familiar actions behind the GLP-1 class.
Glucagon-receptor activation brings a different set of effects. It is associated with increased energy expenditure, meaning the body burns more energy, and with reductions in liver fat. This liver effect is a central part of the mechanistic rationale, because it points toward uses beyond weight and glucose, particularly in metabolic liver disease.
The Liver-Fat Rationale
The interest in the glucagon arm is closely tied to the liver. Reducing fat accumulation in the liver is relevant to metabolic liver conditions now described as MASLD, metabolic dysfunction-associated steatotic liver disease, and its more advanced form MASH, metabolic dysfunction-associated steatohepatitis. Because glucagon-receptor activation is linked to lower liver fat, dual agonists that include a glucagon component have become a focus of research in this area, where effective options have historically been limited.
The Balancing Act
There is a catch that makes the design delicate. Glucagon ordinarily raises blood glucose. On its own, that would work against the goal of improving metabolic health. The GLP-1 component is what offsets this, because its glucose-lowering action counterbalances the glucose-raising tendency of the glucagon arm. The art of a dual agonist lies in getting this balance right, so the energy-expenditure and liver benefits of glucagon come through without undermining glucose control.
Survodutide
Survodutide is a glucagon/GLP-1 dual agonist being developed by Boehringer Ingelheim with Zealand Pharma. It is worth stating the partnership plainly because it is sometimes confused: survodutide is a Boehringer Ingelheim and Zealand Pharma program, not a Roche one. Survodutide has drawn attention for strong liver-fat results in investigation and has received FDA Breakthrough Therapy designation for MASH, a status meant to expedite development of promising treatments for serious conditions. It is a prominent example of the dual-agonist approach aimed squarely at the liver.
Mazdutide
Mazdutide is a glucagon/GLP-1 dual agonist developed by Innovent Biologics, partnered with Eli Lilly. It reached a notable milestone as the first approved GLP-1/glucagon agonist for obesity, approved in China in 2025. That approval makes mazdutide an important real-world data point for the class, showing that a dual agonist of this type has cleared a regulatory bar in at least one major market.
How It Contrasts With Other Approaches
It helps to place dual agonists alongside neighboring designs. GLP-1-only drugs act on a single receptor and are the established backbone of the field. Dual GIP/GLP-1 agents, such as tirzepatide, combine GLP-1 with GIP rather than glucagon, a different second target with its own rationale. Glucagon/GLP-1 dual agonists are distinct again, pairing GLP-1 specifically with glucagon to pursue energy expenditure and liver-fat reduction. Each combination reflects a different hypothesis about which receptors to engage together.
A Research-Framed Summary
The glucagon/GLP-1 class is an active area of metabolic research, with survodutide advancing on the liver-disease front and mazdutide already approved for obesity in China. The underlying logic is consistent: use glucagon-receptor activation for energy expenditure and liver fat, and lean on the GLP-1 component to keep glucose in check. How individual agents perform will continue to emerge from controlled studies and regulatory review.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.